Next Phase Newsletter

By Candice He, Global Investment Strategist, LSN

As a co-organizer of RESI Shanghai, Enmore has become a valuable partner of Life Science Nation, utilizing their expertise in the local market and as conference organizers to make RESI a success, with more than 450 investors, startups and service providers in attendance. LSN and Enmore have a common goal of creating an international ecosystem for advancing life science technologies to market in a global economy, and will continue to partner to achieve this. For those interested in exploring the China market and establishing relationships with key players in the China life science ecosystem, we invite you to attend the Enmore Bio Conference, taking place at the Suzhou International Expo Center from February 20-22, 2020.

What is EBC?

Enmore Bio Conference (EBC) is the largest and most influential bio-industry conference in China, as well as the most open conference platform jointly created by Enmore Healthcare, the organizer, and many industry associations, institutions, companies and experts for the whole industry chain.

EBC consists of four parallel conferences: the 10^th Antibody Drugs & Novel Biological Summit, the 8^th Molecular Diagnostics Summit, the 6^th Immunotherapy Industry Summit, and the 3^rd 17TALK Healthcare Investment & Financing Leadership Forum. The four-in-one event covers topics concerning the whole industry chain of diagnosis, treatment and medication, and other topics like CDx, target development, clinical research and policy discussion will also be touched through a dozen of special forums. The Enmore Bio Exhibition, as part of this event, will attract more than 200 suppliers of instruments, consumables and services. The EBC, which combines conference and exhibition, has become a benchmark platform for high-level exchanges and cooperation in the bio-industry in China and abroad.

Conference website: http://ebc.enmorebiz.com/english.html

Why choose EBC?

EBC is committed to building China’s largest and most influential bio industry event through four parallel conferences, a dozen of co-organized forums, three invited-only meetings for CEOs and pre-event business visits. More than 150 enterprise leaders and experts will make presentations during this event.

Previous reports of EBC:

https://mp.weixin.qq.com/s/h1YQvgaOpClaYRUmNFAmdg

http://ebc2019.enmorebiz.com

Co-organizations of EBC 2020

Guangzhou KingMed Diagnostics Group Co., Ltd.

PersonGene

Wuhan Tongji Hospital

Renmin Hospital Of Wuhan University

Shanghai Junshi Biosciences Co., Ltd.

Hengrui Medcine

Innoforce Pharmaceuticals Co., Ltd.

TOT Biopharm

SAPA-China

Everbright Medical & Healthcare Fund

EBC parallel conferences:

10^th Antibody Drugs & Novel Biological Summit

The 10^th Antibody Drugs & Novel Biological Summit is co-organized by Junshi Biosciences, Hengrui Medicine, Innoforce Pharmaceuticals, TOT BIOPHARM and SAPA-China. It covers the whole process of early research and development, process development, mass production, industrialization and commercialization. We will bring together CEOs and top leaders of functional departments of local listed companies, as well as heads of R&D, production, quality, process and business of antibody enterprises at home and abroad through a platform of exchanges and cooperation for thousands of people.

8^th Molecular Diagnostics Summit

The 8^th Molecular Diagnostics Summit is co-organized by Enmore and KingMed Diagnostics. This time we focus on “molecular diagnostics market structure and corporate strategy”, “multi-platform detection technology for clinical diagnosis” and “to create competitive molecular diagnostic products”. Authoritative experts in precision medicine and outstanding enterprises such as Jiangsu Center for Clinical Laboratories, Shanghai Center for Clinical Laboratory, Berry Genomics, Geneseeq, and KingMed Diagnostics Group will participate in this summit. An invited-only CEO meeting will happen during the summit, organized by Clinical Laboratories leaders.

6^th Immunotherapy Industry Summit

The 6^th Immunotherapy Industry Summit aims to provide businesses with the industrialization of cellular immunotherapy in the next two years. The forum is jointly developed by experts and scholars in the field of cellular immunotherapy study, quality control leaders of first-tier companies, and CEOs of domestic and foreign companies with extensive industrialization experience! Companies and institutions involved include Fosun Kite Biotechnology Co., Ltd, JW Therapeutics, Cellular Biomedicine Group, PersonGene, Tongji Hospital, etc.

3^rd 17TALK Healthcare Investment & Financing Leadership Forum

The 3^rd 17TALK Healthcare Investment & Financing Leadership Forum is co-hosted by Enmore Healthcare and Everbright Medical & Healthcare Fund. The forum features healthcare investment trends and corporate listing, inviting local and international top investors to participate in the discussions. Special financing roadshows will be held to provide a financing platform for enterprises.

Who will attend EBC?

EBC 2019 attracted 2,208 attendees, and EBC 2020 is expected to exceed 3,000 attendees. The participating groups include entrepreneurs, scientists, clinicians, investors and suppliers, mostly CEOs and heads of R&D, production, quality, process and commercialization.

Part of EBC 2019 attendees

Conference Agenda of EBC 2020

Registration at EBC

Online registration:https://ienmore.com/enmoreweb/pc/index.html?language=1&activityId=1267

Consultation: healthcare@enmore.com

By Lucy Parkinson, VP of Investor Research, LSN

At LSN we speak to investors day in, day out, about what technologies they are seeking for their future portfolios. Many are now looking for artificial intelligence (AI) solutions across all of the sectors that LSN covers – drugs, devices, diagnostics and digital health. Investors are interested in the power of AI: from drug discovery tools to data analytics, from genomics to clinical decision support, and also including image analysis and patient monitoring, to name a few.

It’s clear that there is an emerging interest in bringing these fields together. LSN has already used RESI to dip our toes in the water of AI, with regular panels on AI in Healthcare; at RESI Taipei, Professor Jack Li delivered a presentation on the future AI landscape of healthcare, which highlighted the role AI can play in lowering the costs of future care delivery. We’ve found these topics have resonated with both investors and entrepreneurs in early stage life sciences. There are many avenues for adding AI as an extra dimension to new technologies, such as using AI to analyze data from new drugs or devices.

RESI San Francisco will include two investor panels specifically devoted to artificial intelligence: the broad AI in Healthcare panel, and a more focused panel on AI in Pathology and Imaging, a key sector for the advancement of healthcare AI.  AI is also a key topic in other panels such as Oncology Innovation and Investing in Life Science Tools.  With so much innovation happening in this space, RESI hopes to help investors and entrepreneurs who are focused on healthcare AI connect with each other.

LSN is planning further dedicated content in this space; look out for the launch of 4D Meets AI soon.